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Abstract: The distribution of drugs and dietary phenolic compounds in the systemic circulation
de-pends on, among other factors, unspecific/specific reversible binding to plasma proteins such as
human serum albumin (HSA). Phenolic substances, present in plant-derived feeds, foods, beverages,
herbal medicines, and dietary supplements, are of great interest due to their biological activity.
Recently, considerable research has been directed at the formation of phenol–HSA complexes, focusing
above all on structure–affinity relationships. The nucleophilicity and planarity of molecules can be
altered by the number and position of hydroxyl groups on the aromatic ring and by hydrogenation.
Binding affinities towards HSA may also differ between phenolic compounds in their native form
and conjugates derived from phase II reactions. On the other hand, food–drug interactions may
increase the concentration of free drugs in the blood, affecting their transport and/or disposition and
in some cases provoking adverse or toxic effects. This is caused mainly by a decrease in drug binding
affinities for HSA in the presence of flavonoids. Accordingly, to avoid the side effects arising from
changes in plasma protein binding, the intake of flavonoid-rich food and beverages should be taken
into consideration when treating certain pathologies.
Keywords: plasma protein binding; distribution; bioavailability; molecular property; noncovalent
interaction; pharmacokinetics
1. Introduction
The biological activities of dietary phenolic substances, present in plant-derived feeds, foods,
beverages, herbal medicines, and dietary supplements, are of great interest. Polyphenols, which can
be classified as flavonoids and non-flavonoids, contain, in addition to other substituents, at least one
aromatic ring with one or more hydroxyl groups [1,2]. Flavonoids are a group of natural substances
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with variable phenolic structures as flavonols, flavan-3-ols (monomeric and polymeric structures),
flavones, isoflavones, flavanones, and anthocyanidins. On the other hand, stilbenes, hydrolyzable
tannins, lignans, and phenolic acids can be classified as non-flavonoids [3].
The absorption, distribution and elimination of dietary phytochemicals depend on their intestinal
permeability and the influence of pre-systemic enzymes and/or transporters [4]. As systemic exposure
can reflect tissue exposure, greater bioavailability should result in higher levels in tissues. Bioavailability
is defined as the rate and the extent to which the active ingredient/phytochemical or moiety is absorbed
from the ingested matrix and becomes available at the site of action [5]. It is well known that phenolic
compounds have a low oral bioavailability, and undergo an extensive biotransformation mediated by
phase I and phase II reactions in enterocytes and the liver, as well as by gut microbiota [6]. Polyphenol
metabolites are also attracting research interest as their biological effects can be similar to or greater
than those of the parent compounds [6,7]. Paradoxically, despite low oral bioavailability, most of the
phenolic compounds have proven to have significant biological effects [6].
Once a xenobiotic has entered the systemic circulation, its rate of distribution to the various tissues
of the body will be influenced by tissue hemodynamics (blood flow) and the ease with which it can
cross the lipoidal cell membranes, either by passive diffusion or by passive/active facilitated transport
(carrier-mediated) [8]. Nevertheless, the extent of distribution depends on partitioning into fat and
other tissues and on unspecific/specific reversible binding to plasma proteins [9]. Plasma proteins,
also called serum proteins, constitute important organic components consisting of simple as well as
conjugated proteins [10]. Drugs are transported in the circulation either in a free form, dissolved in
the aqueous phase of plasma, or in complex bonds with plasma proteins [11] in varying degrees [12].
Following the principle of reversible equilibrium and the law of mass action [13], an equilibrium
exists between bound and free (unbound) molecular forms—additionally because binding is generally
reversible [12]. Only the free form is capable of diffusing through membranes and from the vascular
space into tissues, being eliminated by metabolism or excretion [14], and therefore pharmacological
activity is exerted by the free drug concentration [15,16]. The fraction of a xenobiotic bound to a
plasma protein depends on protein affinity towards the compound, protein and compound molar
concentration, as well as on the possible competition with other endogenous and exogenous compounds
for binding sites [17]. Generally, acidic compounds tend to bind to albumin, basic compounds to
α1-acid glycoprotein (AAG), neutral compounds can be bound to both human serum albumin (HSA)
and AAG, and neutral lipophilic compounds to lipoproteins. Other proteins, such as α-globulin,
transcortin, fibrinogen, sex-hormone-binding globulin, and thyroid-binding globulin, bind specific
compounds [18,19].
The free drug/xenobiotic concentration depends on the unbound drug clearance and dose, and is
not usually changed by plasma protein binding (PPB) [16]. At a steady state, the free drug concentration
remains balanced on both sides of any biomembrane [16]. As drug clearance occurs, a new equilibrium
between bound and unbound forms is reached, which acts to maintain the free drug fraction [14].
Drug–protein complexes in plasma also serve as a drug reservoir, replacing what is removed by various
distribution and elimination processes [8,15,17,20].
The free drug fraction is the ratio between the free drug concentration and total drug plasma
concentration, which has values between zero (totally bound) and one (totally free), and remains
constant in normal physiological conditions and at low molar drug concentrations. Only if the
free fraction remains constant can the total plasma concentration be considered a good measure of
changes in the unbound drug/xenobiotic concentration. This concept is important because the total
plasma concentration is what is usually measured and not the unbound concentration, which is
only occasionally determined. Although at the therapeutic concentration of most drugs, the molar
concentration of unbound drugs is usually low in comparison with the molar concentration of the
protein binding sites [13,21], in some pathophysiological conditions, the free drug fraction can be
reduced/increased with ensuing changes in the distribution process, either by an altered protein–drug
affinity or by a change in plasma protein levels [16].
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Although it is traditionally considered that only the free form is capable of diffusing through
membranes, recent studies have hypothesized that HSA facilitates Dp44mT delivery to the lysosomes by
internalization through a carrier mediated transport mechanism enhancing its anti-cancer activity [22].
In addition, an in vitro study has shown for proteins with a net negative charge such as albumin,
and for drugs highly bound to albumin and in the physiological albumin concentration range,
a protein-mediated uptake mechanism [23]. It was observed in hepatocytes and cardiac myocytes.
Certainly, this requires further intense investigation since PPB is an important process that determines
the pharmacological activity and pharmacokinetics of drugs and other xenobiotics [12,24], and the
impact of PPB on the efficacy and safety of a treatment needs to be better understood [25].
As with other xenobiotics, the distribution of phenolic compounds to the various tissues of the
body is influenced by unspecific, reversible binding events to plasma protein [9]. PPB and phenolics
have been the subject of numerous recent studies, which have focused above all on structure–affinity
relationships. The aim of this review is to summarize how structural modifications affect the affinity of
the main dietary polyphenols and their metabolites for HSA and to elucidate the main factors involved
in their binding and the binding site. Drug binding properties of HSA and competitive binding with
the most widespread dietary phenolic compounds are also covered.
2. Plasma Proteins
Plasma contains various proteins with different functions including the transport throughout the
circulatory system of endogenous and exogenous molecules. The binding of small molecular weight
drug molecules with plasma proteins is mostly associated with HSA and AAG and, to a lesser extent,
globulins and lipoproteins [26].
HSA is a 66 kDa non-glycosylated monomeric protein of 585 amino acids present in the human
body at a concentration of 0.53–0.75 mM [20,27]. HSA constitutes ~4.5% of the weight of human blood
and helps to maintain osmotic pressure and pH in the blood stream [26,27]. Its principal functions
are to transport fatty acids, hormones, drugs, nutrients and inorganic ions and to buffer pH [28,29].
Due to a large content of ionic residues, HSA is highly soluble in water and its flexibility allows
specific binding to a wide array of molecules [26]. The polypeptide chain of HSA forms a heart-shaped
conformation with approximate dimensions of 80 × 80 × 30 Å, about 67% consisting of α-helices [11,28].
It contains three homologous α-helical domains (I–III), each further divided into two subdomains
(A and B) [30]. Among them, subdomains IIA and IIIA are two important binding sites. They are
delimited by a hydrophobic surface on one side and a positively charged surface on the other side,
displaying well determined cavities to specifically bind neutral and negatively charged compounds.
The globulins (α-globulins, β-globulins, and γ-globulin) are a group of globular water-insoluble
proteins [31]. AAG, also known as orosomucoid, is acidic, heavily glycosylated (38 to 48 kDa protein,
concentration ~12–31 µM), and comprises a single amino acid chain of 204 residues. An acute phase
plasma protein, it is the principal extracellular lipocalin present in blood [32]. Multiple drug-binding
sites have been reported for AAG, but one appears to be most important, particularly for basic and
neutral drugs [8,27]. It should also be considered that if a compound is available as a racemic mixture
in blood/plasma, both HSA and AAG are able to bind preferentially to one stereoisomer [25].
To date, two different approaches to assess drug–protein binding can be distinguished. On one
hand, separative methods used to determine directly either the unbound drug or the bound drug
concentration by separation of the free ligand from the bound species can be classified as conventional
methods (equilibrium dialysis, ultrafiltration and ultracentrifugation), high-performance affinity
chromatography and capillary electrophoresis–frontal analysis. On the other hand, non-separative
methods have been developed to characterize drug–protein interactions. In this sense, spectroscopic
methods (UV–visible, fluorescence, infrared, nuclear magnetic resonance, optical rotatory dispersion,
and circular dichroism) based on the perturbation of electronic and spectroscopic energy levels of the
ligand or the protein and calorimetric techniques (isothermal titration calorimetry and differential
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scanning calorimetry) have been extensively used. In the last year, computational measurements have
also been developed to characterize the polyphenol–protein interactions [1,24].
3. Phenolic Compounds and Plasma Protein Binding
PPB and phenolic compounds have been the subject of numerous recent studies, which have
focused primarily on structure–affinity relationships. The main observations are summarized in
Table 1.
Table 1. Main effect of first pass metabolism of dietary phenolic compounds in human serum albumin
(HSA) binding.




The binding affinity of flavonols for HSA * is
structure-dependent, increasing with the number of
OH groups in the A, B ring.
[33–35]
Glucuronidation Decrease the binding constants. [36,37]
Sulfation Decrease the binding constants. [38]
Flavones
Hydroxylation The HSA affinity of flavones was influenced by thelocation and number of the OH group.
[33,35,39,40]
Hydrogenation Hydrogenation of the unsaturated C2=C3 doublebond can reduce binding affinities for CHPP **.
Methoxylation This reaction enhanced hydrophobicity andhydrophobic interactions increasing affinity for HSA. [33,35,40]
Isoflavones Hydroxylation
The hydroxylation at positions 5 and 7 on the A ring
increased HSA binding affinity rates.
A weakening of isoflavones binding affinities for





The C2=C3 double bond conjugated with the oxo
group at C-4 plays an important role in flavanone
affinity for plasma proteins.
[40]
Hydroxylation
Affinity increased by the addition of a hydroxyl
group on the A ring (C-5 and C-7) and the B
ring (C-2’).
[35]
Methoxylation Slightly increased the protein binding rate. [40]
Glucuronidation Glucuronidation in the B-ring weakly destabilizesthe flavanone-HSA complex. [41]
Flavan-3-ols Hydroxylation
The number of hydroxyl groups on the B ring and
the presence of a galloyl (3,4,5-trihydroxybenzoyl)
moiety increase binding affinities for HSA.
[42–44]
Anthocyanidins
Hydroxylation The binding affinities increase with the number ofhydroxyl groups on the B ring. [45–47]





In the case of benzoic acid, the introduction of (1) an
OH group at C-2 on the benzene ring exerted a
positive effect and (2) a hydroxy substituent at C-4
had a negative influence.
[48]
Methoxylation
Both methylation of the hydroxy groups and
substituting the hydroxy groups with methyl groups
at C-3 and C-4 on the benzene ring resulted in an
increase of binding affinity.
Hydroxycinnamic
acids
Minimal modifications of the chemical structure led
to significant changes in binding. [49–52]
Stilbenes
Hydroxylation The stilbenoid–HSA affinity was increased. [35,53]




The intensity of the interaction depends not only on
the number of OH groups, but also on the bulk,
flexibility and hydrophobicity of the chemical
structure.
[55,56]
* HSA: human serum albumin; ** CHPP: common human plasma protein.
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3.1. Flavonoids
Flavonoids are the major polyphenols in a wide variety of plant sources. Associated with antiaging,
antifungal, anti-inflammatory, and anticancer activities, they exhibit high reactivity with reactive
oxygen species such as hydroxyl, alkoxyl, or peroxyl radicals and efficiently inhibit lipid peroxidation
in micelle systems [57]. They have a tricyclic structure in which a phenyl (B ring) is attached at position
two or three of a benzopyrone or benzopyran system (AC rings), [1] as shown in Figure 1. The most
common sub-classes of flavonoids are flavonols, flavones, isoflavones, flavanones, flavan-3-ols, and
anthocyanidins, which are differentiated by the structural features of the C ring [2]. The interactions
between flavonoids and plasma proteins have been extensively studied. In 2018, it was found that the
position of hydroxyl groups and the presence/absence of an unsaturation between C2–C3 in flavonoids
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Figure 1. Chemical structure of flavonoids.
3.1.1. Flavonols
Flavonols (3-hydroxyflavones) are compounds with medium nucleophilicity and a partial positive
charge at the C-3 position [39]. Given that flavonoids are present in the blood circulation mainly as
conjugates resulting from phase II metabolic reactions, it is important to know the affinity of flavonoid
conjugates for albumin rather than that of their native forms. In this sense, the study of Dufour and
Dangles estimated that the majority of flavonol conjugates (more than 80%) circulate bound to albumin
rather than in their free form [38]. This transport through the blood circulation is essential for its further
delivery at the cell surface, and consequently, membrane uptake to finally produce its biological effect.
In this sense, the binding would facilitate the uptake of circulating flavonol conjugates into tissues.
Structurally, the binding affinity of flavonols for HSA is structure-dependent, increasing with
the number of OH groups: the addition of a hydroxyl group at C-5 (A ring) increased the binding
rate of fisetin with common human plasma proteins (CHPP) by 11.48% [33]. The same occurs
for the B ring where the binding constants were in the following order: myricetin > quercetin >
kaempferol [34]. Additionally, hydroxylation at C-4’ (B ring) slightly increased the binding affinity of
3,4’-dihydroxyflavone (88.77 ± 0.07%) compared to 3-hydroxyflavone (87.78 ± 0.03%) [35] and reduced
that of galangin [33].
Quercetin, one of the most abundant flavonoids in our diet, mainly binds to HSA (subdomain IIA),
followed by AAG and with no substantial interaction with very-low-density lipoproteins (99.4 ± 0.1,
39.2 ± 0.5 and <0.5%, respectively) [58]. The binding constants determined for the glucuronide form of
quercetin were lower compared to the parent compound, but the stability of quercetin-3-glucuronide
and isorhamnetin-3-glucuronide complexes was still high enough to significantly interact with HSA [36].
The main reasons why the glucuronidated form of quercetin had less affinity for HSA are: (1) formation
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of an intermolecular hydrogen bond or an ionic interaction between the hydroxyl group of quercetin
(C-3) and the nitrogen atom of Lys195 [37]; (2) for steric reasons, the presence of the bulky polar
substituent (position three) may reduce the PPB affinity of this metabolite; (3) lower complex stabilities
due to the absence of interaction of the 3-hydroxyl moiety with Lys195 [36]. On the other hand,
the binding experiments reveal that quercetin sulfate lowers its affinity to albumin by one order of
magnitude [38]. However, contradictory results were obtained in the study in which the sulfate form
of quercetin (quercetin-3’-sulfate) bound to HSA slightly more readily than quercetin [36].
3.1.2. Flavones
Flavones are compounds with medium to high nucleophilicity and a medium partial negative
charge at C-3 [39]. Similar to flavonols, these hydrophobic compounds display stronger binding
affinities for HSA (higher binding constants) than the other flavonoids [39,59].
Changes in flavone affinity for HSA and CHPP after oxidation or conjugation reactions have been
studied. The introduction of a hydroxyl group on the A ring enhanced the HSA binding rate [35].
Another study has found that the optimal number of hydroxyl groups on the A ring of flavone
7-hydroxyflavone, 5,7-dihydroxyflavone (chrysin), and baicalein was one, and the affinities for HSA
decreased with the addition of more hydroxyl groups at positions C-5, C-6, and/or C-7 [60]. In 2016,
Rimac and coworkers demonstrated that the HSA affinity of flavones was influenced by the location of
the OH group, which had an enhancing effect when attached at C-4 on the A ring [39]. Regarding the
B ring, the same authors found that after hydroxylation, apigenin had less affinity than chrysin (1.32 ±
0.05 × 105 and 1.95 ± 0.08 × 105 M−1, respectively) [39]. Hydroxylation at C-3’ slightly enhanced flavone
binding affinity for HSA, which was about 1.38-fold higher in luteolin compared to apigenin [40],
a difference that increased to 1.74-fold for CHPP [33]. Hydroxylation of the C ring resulted in a 12.5%
higher protein binding rate in 3-hydroxyflavone compared to flavone [35]; hydroxylation at C-3 also
increased the affinity of luteolin for CHPP, but little effect was observed in chrysin and apigenin [33].
Hydrogenation of the unsaturated C2=C3 double bond of flavone, 6-hydroxyflavone,
and 6-methoxyflavone reduced binding affinities for CHPP by 10.02- to 17.82-fold, but had hardly
affect in apigenin and 7-hydroxyflavone [33]. This structural modification had a similar outcome on the
affinity of flavone, 6-hydroxyflavone and 7-hydroxyflavone for HSA [35]. The explanation is that the
reaction modified the flavonoid C ring from a planar to a twisted structure [33], also reducing polarity,
and molecules with a non-planar structure were unable to enter the hydrophobic pockets in HSA [35].
Planarity is therefore an important prerequisite for flavonoid binding in the hydrophobic cavity [39].
Methoxylation increased tangeretin affinity for HSA 100-fold, mainly attributed to enhanced
hydrophobicity and hydrophobic interactions [40]. Compared to flavone, the affinity of
6-methoxyflavone was slightly higher, whereas a slightly lower affinity was observed when a hydroxyl
group was substituted by a methoxy group (methylation) (6-methoxyflavone < 6-hydroxyflavone) [33].
The same behavior was observed with 5-methoxyflavone and 6-methoxyflavone, whose affinity was
reduced by 20% and 4%, respectively. The more methoxy groups were added, the more the protein
binding rate decreased (tangeretin > nobiletin) [35].
3.1.3. Isoflavones
Soybean and derived food products are the main sources of dietary isoflavones [1], above all
genistein, daidzein and glycitein [61]. Isoflavones have low nucleophilicity and a low partial negative
charge [39]. Studies on genistein have indicated it binds to HSA via polypeptide polar groups with
overall binding constants of 2.4 ± 0.40 × 104 M−1 [62] and 1.5 ± 0.2 × 105 M−1 [61]. In the same study,
the genistein–HSA complex was found to preclude the attachment of daidzein due to competitive
binding. The hydroxylation of isoflavones at positions five and seven on the A ring increased HSA
binding affinity rates [35]. This is in contrast with Xiao and coworkers [33], who reported a weakening
of isoflavone binding affinities for CHPP after C-5 hydroxylation of the A ring; similar behavior was
observed for HSA after C-3’ hydroxylation of the B ring (formononetin > calycosin) [35].
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3.1.4. Flavanones
Flavanones have very low nucleophilicity and a high partial negative charge at C-3 on the C
ring [39]. In 2011, Cao and coworkers demonstrated that the C2=C3 double bond conjugated with the
oxo group at C-4 played an important role in flavanone affinity for plasma proteins; hence, the affinity of
apigenin for HSA is about 10,000-fold higher than that of naringenin [40]. Moreover, affinity increased
by the addition of a hydroxyl group on the A ring (at C-5 and C-7) and the B ring (at C-2’) [35]. Regarding
methoxylation, the addition of a methyl group at position six on the A ring of flavanone slightly
increased the protein binding rate [35] and increased the affinity of tangeretin for HSA 100-fold [40] by
polarity reduction and capacity improvement to penetrate the tryptophan-rich hydrophobic regions of
HSA [40]. Finally, and considering glucuronidation, it showed weakly destabilized flavanone–HSA
complexes and the effect was slightly stronger than if it had occurred in the B ring [41].
3.1.5. Flavan-3-Ols
The subclass of the flavonoid family known as flavan-3-ols includes catechins and plant phenols
widely distributed in various fruits, red wine, juices, and cocoa, with green tea being the richest dietary
source [63]. The number of hydroxyl groups on the B ring and the presence/absence of a galloyl
(3,4,5-trihydroxybenzoyl) moiety are responsible for the functional differences in catechins such as
(−)-epigallocatechin, (−)-epicatechin, (−)-epicatechin gallate and (−)-epigallocatechin gallate [42,43].
Thus, those with the galloyl moiety showed enhanced hydrophobic properties and consequently higher
binding affinities for HSA than catechins lacking this substituent [43,44]. Differences in protein affinity
have also been found among stereoisomeric flavan-3-ols [64]. The binding constant (Ka) obtained
for (+)-catechin–HSA lies in the intermediate range, not being so low that it leads to an inefficient
distribution or so high that it lowers the plasma concentration [42]. The number of binding sites found
for the catechin–HSA systems range from 0.87 to 1.10, suggesting that one HSA molecule associates
with one catechin molecule [63].
3.1.6. Anthocyanidins
Anthocyanins are water-soluble pigments found throughout plants but are most obvious in fruits
and flowers, presenting a spectrum range from pink, red and violet to dark blue [45,46]. The basic
chemical structure of anthocyanins is 3,5,7-trihydroxy-2-phenylbenzopyran and they can be classified
according to whether they are glycosylated or not, as well as by the number and location of hydroxyl
or methoxyl groups and their substituents on the rings [45]. Thus, under physiological pH conditions,
the number and position of the hydroxyl groups on the B ring affected anthocyanin affinities for HSA,
which increased with the number of groups [45–47]. This effect can be explained considering that at pH
7.4 quinoidal and anionic quinoidal bases are major species, which favor hydrogen bonding and other
types of electrostatic forces [47]. On the other side, the influence of methoxylation and glycosylation
could either strengthen or reduce the anthocyanin affinity for HSA [46,47].
3.2. Phenolic Acids
Phenolic acids, including benzoic and cinnamic acids, are the predominant type of polyphenols in
fruits, vegetables, and most plant-derived beverages [49]. Structurally, they derive from benzoic or
cinnamic acid, as shown in Figure 2.
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Figure 2. Chemical structure of representative phenolic acids. General chemical structure of stilbenes
and hydrolysable tannins.
3.2.1. Hydroxybenzoic Acids
Ellagic acid, a pharmacologically beneficial polyphenol found in fruits (grapes, strawberries,
blackcurrants and raspberries) and nuts [65–67], formed a c mplex with HSA with a binding affinity
constant of 15.5 × 104 M−1 [65]. In 2014, He and coworkers demonstrated that ell gic acid binds to
HSA more strongly than oleuropein [68]. In the case of benzoic acid, the introduction of different
numbe s and arrangements of hydroxy groups and other substituents n the aromatic ring altered the
binding affinities as follows: (1) a hydroxy group at C-2 on the benzene ring exerted a positive effect;
(2) a hydroxy sub tituent at C-4 had a negative influenc ; and (3) both m thylation of the hydroxy
groups and ubstitution of the hydroxy groups with methyl gr ups at C-3 and C-4 on the benzene ring
resulted in an i crease [48].
3.2.2. Hydroxycinnamic Acids
The most representative hydroxycinnamic acids are caffeic acid, chlorogenic acid, and caffeoyl
quinic acids [1]. Th association consta ts (K) for the HSA– hlorogenic acid interaction at 10, 25
and 40 ◦C were 6.0 × 104, 9.0 × 103 and 2 × 104 M−1, respectively [69], indicating the involvement
of two major forces in the binding process. Sim lar results were report d by Kang and coworkers
(4.37 × 104 M−1) [50]. The format on of a biomolecula complex between chlorogenic acid and its
derivatives with HSA was also st died by Sinisi and colleagues [70]; the reported dissociation constants
indicated a very high affinity for this family of compounds, and min mal modifications of th chemical
structure led to significant changes in bindi g. In another study, the binding affin ty of chlorogenic
acid and its isomers for HSA ranked in the decreasing order: cryptochlorogenic acid > neo hlorogenic
acid > chlorogenic cid; the 4-esteryl structure was associated with a higher binding affinity and larger
conf rmational changes than the 3- or 5- steryl stru tur s [51]. The binding constant of HSA complexes
was calculated to be 4.29 × 104 M−1 at 298 K for ro marinic acid [49] and 2.23 × 104 M−1 for ferulic
acid [50]. Cinnamic acid and its hydroxyl derivatives interacted with HSA in the ecreasing order of
caffeic aci > p-coum ric acid > cinnamic acid [52].
3.3. Stilbenes
Stilbenoids are an important group of phenolic compounds with a C6-C2-C6 carbon skeleton
structure [1], as shown in Figure 2. Among them, resveratrol, found largely in the skin of red
grapes and wine, binds to HSA with an association constant of 2.56 × 105 M−1 [71]. The effect of
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hydroxylation of stilbenes has been studied in the context of the structure–affinity relationship of
stilbenoid–HSA systems. It has been recently demonstrated that the addition of a hydroxyl group to
resveratrol (piceatannol and oxyresveratrol) on the B ring increases the binding rates [35]. In addition,
hydroxylation increased the binding affinities of stilbenoids for HSA (pterostilbene > pinostilbene >
oxyresveratrol > piceatannol > resveratrol > isorhapontigenin > piceid) [53]. The stilbenoid–HSA
affinity was reduced by methylation (resveratrol > pterostilbene) [54] and enhanced by methoxylation
at C-3 or C-5 of resveratrol [53].
3.4. Hydrolysable Tannins
Little is known about the structural and functional relationship between plasma proteins and
tannins. Sekowski and coworkers demonstrated that hydrolysable tannins interact very strongly with
HSA, with an intensity of the interaction that depends not only on the number of hydroxyl groups,
but also on the bulk, flexibility and hydrophobicity of the chemical structure [55,56]. Tannins with
higher molecular weight bind with stronger interaction to proteins, but also tannin flexibility has
to be considered: the more flexible the structure, the more rotational capacity of the molecule and
easier access to protein binding pockets [55]. Thus, larger and more flexible molecules are capable of
changing the secondary structure of albumin through surface interactions, but the presence of valoneoyl
structures limit the capacity of tannins to penetrate the hydrophobic tryptophan pocket [55,56].
4. Interactions between Phenolic Compounds and Plasma Proteins
4.1. Non-Covalent Bonds
Phenolic compounds, under non-oxidative conditions, form reversible complexes with plasma
proteins [72,73] involving hydrogen bonds, electrostatic interactions, hydrophobic effects and van der
Waals forces [45,72,73]. The interactions between polyphenols and proteins are determined by the
thermodynamic parameters of enthalpy (∆H◦) and entropy (∆S◦). Positive values of both parameters
indicate a hydrophobic interaction; negative values point to van der Waals forces and hydrogen
bonding; and ∆S◦ > 0 and ∆H◦ ≈ 0 indicate that an electrostatic force plays a vital role in aqueous
solutions [74].
The attraction between the aromatic ring of the polyphenol and hydrophobic regions of other
compounds (aliphatic and aromatic side chains of amino acids) leads to the formation of hydrophobic
bonds [75]. These bonds arise from changes in entropy rather than enthalpy and are reversible and
independent of pH [75]. Hydrogen bonds involve the sharing of a phenolic proton with numerous
amide carbonyl moieties of HSA and occur only in the presence of phenoxyl hydrogen. On the other
hand, ionic bonds are only generated when polyphenols are ionized to highly reactive phenolate ions.
Electrostatic attraction between the phenolate ion and cationic portions of other compounds leads to
the formation of this bond [75].
The nature of phenol–protein complexes depends heavily on individual phenolic structures,
and the spatial arrangements of substituents seem to be key factors in phenol–HSA affinities [57,72].
In genistein–HSA complexes, hydrophobic and electrostatic interactions play a central role in the
binding [76], although the involvement of hydrogen bonds and ionic interactions has also been
suggested [61]. The binding between naringin and HSA strongly involves hydrophobic interactions,
according to the positive values of ∆H◦ and ∆S◦, but the involvement of electrostatic interactions cannot
be ruled out [77]. The nitrogen atom of Lys195 is suitably positioned to establish an intermolecular
ionic interaction with the hydroxyl at C-3 in quercetin [37].
To date, numerous studies on flavanone–HSA complex formation have suggested the involvement
of: (1) hydrogen bonds between the phenolic hydroxyl groups and the polypeptide chain or polar
amino acid residues; (2) hydrophobic interactions between the aromatic ring and hydrophobic amino
acid residues; (3) electrostatic forces generated after the deprotonation of the acidic phenolic hydroxyl
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group in the A ring (hesperetin) by the basic amino acid residues; (4) perpendicular and parallel π−π
interactions and (5) van der Waals forces [78–81].
There is considerable evidence that catechins bind to HSA via hydrophobic and hydrogen
bonding [63,64,82]. It has been demonstrated that hydrogen bonding and van der Waals forces are
predominant in (+)-catechin–HSA complexes [42]. However, thermodynamic parameters indicate that
tea catechins bind serum proteins via ionic interactions (+∆S◦ 18 to 9 J mol−1 K−1 and −∆H◦ −13 to
−8 kJ mol−1) [82].
As anthocyanins are transported in the circulation system, small molecules bound to plasma
proteins are exchanged with their free form in order to maintain an equilibrium [29]. Various studies
have focused on the structure–molecular affinity relationship of the anthocyanin–HSA interaction.
The van der Waals forces, hydrogen bonds, hydrophobic effect and electrostatic forces are the main
drivers of the anthocyanin–protein complex formation [29,47]. The strength of anthocyanin binding to
HSA is affected by factors such as pH, temperature, and chemical structure. Thus, the hydrophobic
effect plays a major role at pH 4 but is less important at pH 7.4. Moreover, at pH 7.4, the association
constant of HSA with aglycones bearing an increasing number of hydroxyl groups indicates the
importance of attractive electrostatic interactions such as hydrogen bonding between polar groups [47].
Hydrophobic forces and hydrogen bonds are predominant in the HSA binding interactions
with phenolic acids and their methyl esters, respectively [48], as well as with ellagic acid [65,66,68];
the involvement of van der Walls forces has also been proposed [67]. Gallic acid is reported to bind to
HSA mainly by hydrophobic and electrostatic interaction in microemulsions [83].
Little is known about the structural and functional relationships in tannin–HSA and
stilbenoid–HSA complexes. Tannin interaction with plasma proteins was recently described as
complex and opportunistic, occurring without specific binding sites and determined mainly by
hydrophobic forces and hydrogen bonds [55,56]. On the other hand, the hydrophobic interaction is the
main force binding stilbenoids with HSA [53]. Regarding resveratrol, structural analysis showed that
it binds non-specifically (H-bonding) via polypeptide polar groups [71].
4.2. Hydrolysable Tannins
Highly reactive with oxygen species, many polyphenols can be oxidized to their corresponding
semiquinones and quinones, which may then undergo covalent reactions with an enormous number of
nucleophiles [73], such as amino acids or thiol groups [72]. In this context, covalent bonds can be formed
between a phenolic or quinone carbon ring and plasma proteins. The irreversible polyphenol–protein
covalent bindings influence the chemical properties of both species, are resistant to disruption by
denaturing agents [73,84,85], and can be formed enzymatically and non-enzymatically [75]. Regarding
phenolics, covalent bonds are the result of their electrophilic substitution at the ortho and para
positions. On the other hand, conjugate addition reactions to the unsaturated carbonyl moiety
lead to the formation of covalent bonds with quinones. The differences in the location and type
of substituents are a result of differences in electron densities and distribution both in phenols and
quinones. The phenolic polymerization through covalent bonds by oxidative processes (generating
phenoxyl radicals), or by condensation reactions between polyfunctional nucleophiles (including the
anions derived from polyphenols) and quinones can also be formed [75]. Covalent reactions can
change the protein structure with a corresponding modification of hydrophobic–hydrophilic properties
of the protein derivatives, accompanied by a change in solubility [73].
In 2005, Kaldas and coworkers demonstrated in an in vitro study that quercetin oxidized by
peroxidase/hydrogen peroxide covalently links to proteins, mainly with a high affinity for HSA [84].
However, in 2010, Cahyana and Gordon reported that non-covalent binding occurred between HSA
and anthocyanins with a quite weak negative value of Gibbs free energy (∆G◦, −28.2 to −36.3 kJ mol−1),
which is much lower than the value for covalent bond formation (approximately 400 kJ mol−1) [47].
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5. Binding Sites
HSA contains three homologous α-helical domains (I–III), each further divided into two
subdomains (A and B) [30]. Subdomains IIA and IIIA (Sudlow’s sites I and II, respectively) are
primary binding sites at which many drugs can bind, with IIA being the most prominent. In this
sense, bulky heterocyclic anions with the charge located in a central position of the molecules (such as
warfarin) are generally attached at the I site of HSA, while aromatic carboxylic acids with an extended
conformation and the negative charge located at one end of the molecule (such as ibuprofen) bind at
site II [11,38,79,85].
The IIA subdomain appears to be spacious and is comprised of several individual binding sites that
can accommodate ligands with a great variety of chemical structures. In contrast, the IIIA site is smaller
and less flexible and can only accept structurally similar ligands [39]. The protein microenvironment
of site I of HSA is rich in polar (basic) amino acid residues, which are able to stabilize the negatively
charged ligand bound in non-planar conformation [37].
In 2005, Dufour and Dangles proposed that the binding of flavonols mainly takes place in
subdomain IIA. Computational mapping of possible binding sites of quercetin revealed binding in
the large hydrophobic cavity of subdomain IIA [37], similar to that reported for kaempferol [86],
hesperetin [79] and apigenin [87].
The higher affinity of flavones for HSA possibly relies on the benzopyrone moiety (AC rings), which
protrudes from the hydrophobic cavity and points towards the entrance of site I, as the hydrophilic
phenolic hydroxyl groups can interact with nearby polar residues [88]. However, methoxylation
decreased flavone polarity and improved the ability to penetrate the tryptophan-rich hydrophobic
regions of proteins, which are often buried in the interior of the folded proteins [40]. To date, it is
known that the HSA conformation is altered by binding to trimethoxy flavone, with a decrease in
α-helix content and an increase in β-sheets and random coils, suggestive of the partial unfolding of the
secondary structure of the protein [89].
The identification of a binding pocket in HSA for isoflavones suggests daidzein and genistein
are bound to the subdomain IIA [61]. Structural differences between curcumin and genistein did
not affect the hydrophobic binding affinity for HSA and therefore both are mainly bound in the
hydrophobic pockets of Try 214 in site I [62]. Moreover, structural analysis demonstrated that curcumin
and genistein bind to HSA via polypeptide polar residues and that the HSA conformation is altered
by their complexation, with a reduction in α-helix content and an increase in random coil and turn
structures, again indicating a partial protein unfolding [62].
Similar to the other flavonoids, the primary binding site for flavanones is in the subdomain IIA,
but it is located closer to the binding site in IIIA [40,77,78,80,81]. The alteration of the protein secondary
structure has also been studied [77]. When the flavanone concentration was increased, the percentage
of protein α-helix structure gradually decreased [77,79], which implied a rearrangement of the carbonyl
hydrogen bonding network of the main polypeptide chain of the protein [78,79]. The flavanones
entered the hydrophobic binding cavity located in subdomain IIA by hydrophobic interactions, and the
phenolic hydroxyl groups interacted through strong hydrogen bonds with C=O and N–H of the
main polypeptide chain, resulting in the aforementioned rearrangement of the polypeptide carbonyl
hydrogen bonding network, and a consequent reduction in the protein α-helix structure [79].
A site marker competitive experiment has demonstrated that (+)-catechin is mainly located within
site I of HSA [42] and (±), (+), and (−) forms of catechin bind in the proximity of Trp-214 of HSA [64].
Additionally, studies on conformational changes in plasma protein after binding with flavan-3-ols
have reported that galloylated catechins increased the electrophoretic mobility of HSA, which reflects
a modification of its molecular charge [44,63]. Changes in the α-helicity of the (±), (+), and (−) forms
of catechin were found to be marginal [64].
Protein conformational changes can also be attributed to the presence of anthocyanins. Interaction
of HSA with keracyanin causes changes in the polarity of the hydrophobic microenvironment.
The binding site of keracyanin might be in the hydrophobic cavity, the location of Trp-214 and at the
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center of the three domains of HSA, which induces slight unfolding or adaptive rearrangement of the
polypeptide backbone of the protein [29].
Structural differences affect the binding site of hydroxybenzoic acids. In 2009, a study revealed
that protocatechuic acid and its partially methylated products bind to HSA in sites I and II. In contrast,
the addition of a hydroxyl group from protocatechuic acid, yielding gallic acid, did not result in
competitive binding in sites I or II [90]. An evaluation of the bioactive interaction indicates that the
HSA residues for ellagic acid binding are located in subdomain IIA [66] and that the mode of binding
reaction is spontaneous [67], which would suggest an alteration of the protein secondary structure.
According to circular dichroism spectroscopic data, the fraction of alpha helicity was reduced from 52%
to 40% upon binding to ellagic acid [65]. Both ellagic acid and oleuropein interact with the binding
pocket of HSA in subdomain IIA [68]. In another study, it has also been demonstrated that gallic acid
could bind to the site I of HSA [83].
Differences between hydroxycinnamic acid binding sites have also been studied. Binding with
chlorogenic acid induces conformational change in HSA, involving the one tryptophan residue in
the binding region [51,69]. The binding of chlorogenic acid and rosmarinic acid most likely takes
place in site I and ferulic acid in site II [49,50]. Chlorogenic acids and their derivatives, which are
abundant in coffee, form a bimolecular complex within Sudlow’s site I and interact with Trp-214 [70].
Multispectroscopic and docking studies on the binding of chlorogenic acid isomers with HSA show
that three isomers bound to HSA at Sudlow’s site I, affecting the protein secondary structure [51].
Chlorogenic acid is thought to bind in subdomain IIA and ferulic acid in IIIA [50]. In another study,
it has been demonstrated that after the interaction between HSA with caffeic acid, p-coumaric acid and
cinnamic acid, the α-helix structure was reduced by 9, 5 and 3%, respectively) [52]. Finally, in 2015, Nair
demonstrated through experimental and theoretical studies that both resveratrol and pterostilbene
bind to the hydrophobic cavity at site IA in the subdomain II of HSA [54].
6. Phenolic Compounds–Drug Interaction
Data on food–drug interactions are generally scarce, despite some well documented exceptions
(e.g., grapefruit juice and statins), as food consumption and herbal teas/beverages are not usually
monitored in patients. Interactions occur after the concomitant intake of food and drugs, with impacts
on the absorption and/or metabolism of the active substance. In some cases, the effects of the interactions
may benefit the patients, but they frequently undermine the efficacy of the drug or induce adverse
reactions [91].
In the case of PPB, a hormone, drug or even a toxin can be displaced by competing
phenolic compounds and then circulates in the blood in a free form. The pharmacodynamics
and pharmacokinetics of a drug may subsequently be modified, potentially leading to stronger
pharmacological activity, adverse effects and faster elimination [39]. It should be noted that such
effects are rarely caused by the formation of phenol–HSA complexes, as the low phenol and high HSA
concentration in plasma renders saturation at the binding site unlikely. Moreover, phenolic compounds
are often subject to high first-pass metabolism, and thus it is the conjugated-HSA complex that should
be taken into account in a potential food–drug interaction. Nevertheless, such an outcome should be
kept in mind for drugs with high PPB, a low extraction ratio and narrow therapeutic index, and for
other plasma proteins more specific than HSA.
To date, most of the research on food–drug interactions has been focused on flavonoids and HSA.
Rutin and baicalin have been extensively used to determine the effect of flavonoids on the binding
properties of cleviprex, theophylline, nifedipine, promethazine and ticagrelor [91–95]. The results show
that (1) both hydrogen bonds and hydrophobic interactions play a central role in the binding process,
which is spontaneous; (2) flavonoids can reduce the association constant and increase the distance of
drugs binding to HSA due to competitive binding at site I; (3) the synergistic effect of drugs with rutin
and baicalin can further change the HSA conformation, and (4) reduced affinities of drugs binding to
HSA in the presence of flavonoids may lead to an increase in free drugs in the blood, which would
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Figure 3. Dietary flavonoid–drug interaction mechanism.
Quercetin had the same effect as rutin and baicalin on ticagrelor and propranolol binding to
HSA [95,96]. In 2012, Maciazek-Jurczyk and collaborators reported that competition from curcumin
for the binding site of tamoxifen in HSA reduced the binding affinity of this chemopreventive agent,
which increased its unbound fraction in the blood with potentially toxic effects [97]. In 2017, Rimac and
colleagues showed that warfarin–flavonoid interactions should be regarded as negligible, as they do
not share the same binding region in HSA [98]. Conversely, in the same year, it was demonstrated that
quercetin metabolites strongly displace warfarin when binding to HSA, suggesting that high quercetin
levels can negatively interfere with warfarin therapy [36].
Consequently, the intake of flavonoid-rich foods and beverages should be reduced during
treatment with the aforementioned drugs to avoid food–drug interactions and the incidence of toxic
symptoms. Alternatively, drugs that do not share the same binding region as flavonoids can be used.
7. Conclusions
PPB is a key process that determines the pharmacokinetics (distribution, metabolism,
and elimination) and effects of many drugs and dietary phenolics in the body. This review has
gathered valuable information concerning the binding of dietary polyphenols to HSA, highlighting
how the properties of these compounds can be substantially modified after the formation of a protein
complex. The structural differences among flavonoids, phenolic acids, stilbenes, and hydrolysable
tannins strongly affect the binding process with plasma proteins. Thus, the formation of a phenolic–HSA
complex is affected by phase I reactions. The number and position of substituted hydroxyls on the
aromatic ring of the compounds and hydrogenation can alter the nucleophilicity and planarity of
molecules. The binding affinities of phenolic compounds towards HSA are also affected by phase II
reactions (glucuronidation, methylation, methoxylation and sulfation). Accordingly, in order to avoid
potential therapeutic failures caused by food–drug interactions, the intake of flavonoid-rich food and
beverages should be monitored when treating certain pathologies.
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